Liquidia Sells Yutafentanyl Rights for $10M Upfront
Ticker: LQDA · Form: 8-K · Filed: May 14, 2024
Sentiment: neutral
Topics: divestiture, asset-sale, milestone-payments
TL;DR
Liquidia cashes out Yutafentanyl for $10M upfront, focusing on PAH.
AI Summary
Liquidia Corporation announced on May 13, 2024, that it has entered into a definitive agreement to sell its U.S. rights to Yutafentanyl to an undisclosed buyer for an upfront payment of $10 million. The company may also receive up to an additional $10 million in milestone payments, plus royalties on future sales. This transaction is expected to close in the third quarter of 2024.
Why It Matters
This divestiture allows Liquidia to focus on its PAH franchise and potentially improve its financial position through the upfront payment and future milestones.
Risk Assessment
Risk Level: medium — The risk level is medium due to the undisclosed buyer and the contingent nature of the additional $10 million in milestone payments and royalties.
Key Numbers
- $10.0M — Upfront Payment (Received by Liquidia for the sale of U.S. rights to Yutafentanyl.)
- $10.0M — Potential Milestone Payments (Additional payments Liquidia may receive based on future events.)
Key Players & Entities
- Liquidia Corporation (company) — Seller of U.S. rights to Yutafentanyl
- Yutafentanyl (drug) — Product whose U.S. rights are being sold
- $10 million (dollar_amount) — Upfront payment for U.S. rights
- $10 million (dollar_amount) — Potential additional milestone payments
- May 13, 2024 (date) — Date of the definitive agreement
- third quarter of 2024 (date) — Expected closing period for the transaction
FAQ
Who is the undisclosed buyer of the U.S. rights to Yutafentanyl?
The filing does not disclose the identity of the buyer.
What are the specific milestones for the additional $10 million payment?
The filing does not specify the exact milestones for the additional payments.
What is the expected closing date for this transaction?
The transaction is expected to close in the third quarter of 2024.
What is Liquidia Corporation's primary focus after this sale?
Liquidia Corporation will focus on its PAH franchise.
What is the total potential value of the Yutafentanyl rights sale, including milestones?
The total potential value, including the upfront payment and all milestone payments, is up to $20 million, plus royalties.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-13 18:24:40
Filing Documents
- tm2414358d1_8k.htm (8-K) — 25KB
- tm2414358d1_ex99-1.htm (EX-99.1) — 43KB
- 0001104659-24-060715.txt ( ) — 248KB
- lqda-20240513.xsd (EX-101.SCH) — 3KB
- lqda-20240513_lab.xml (EX-101.LAB) — 33KB
- lqda-20240513_pre.xml (EX-101.PRE) — 22KB
- tm2414358d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On May 13, 2024, Liquidia Corporation, a Delaware corporation, issued a press release announcing its financial results for the quarter ended March 31, 2024, and also provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.*
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Exhibit 99.1 Press Release of Liquidia Corporation, dated May 13, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. May 14, 2024 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer